Abstract
Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles and neuronal loss. Amyloid-β protein (Aβ) deposition plays a critical role in the development of AD. It is now generally accepted that massive neuronal death due to apoptosis is a common characteristic in the brains of patients suffering from neurodegenerative diseases, and apoptotic cell death has been found in neurons and glial cells in AD. Melatonin is a secretory product of the pineal gland; melatonin is a potent antioxidant and free radical scavenger and may play an important role in aging and AD. Melatonin decreases during aging and patients with AD have a more profound reduction of this indoleamine. Additionally, the antioxidant properties, the anti-amyloidogenic properties and anti-apoptotic properties of melatonin in AD models have been studied. In this article, we review the antiamyloidogenic and anti-apoptotic role of melatonin in AD.
Keywords: Alzheimer disease, neurodegeneration, neuroprotection, melatonin, amyloid beta-protein, amyloid precursor protein, apoptosis, mitochondria
Current Neuropharmacology
Title: Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease
Volume: 8 Issue: 3
Author(s): Hongwen He, Weiguo Dong and Fang Huang
Affiliation:
Keywords: Alzheimer disease, neurodegeneration, neuroprotection, melatonin, amyloid beta-protein, amyloid precursor protein, apoptosis, mitochondria
Abstract: Alzheimer disease (AD) is an age-related neurodegenerative disorder characterized by the presence of senile plaques, neurofibrillary tangles and neuronal loss. Amyloid-β protein (Aβ) deposition plays a critical role in the development of AD. It is now generally accepted that massive neuronal death due to apoptosis is a common characteristic in the brains of patients suffering from neurodegenerative diseases, and apoptotic cell death has been found in neurons and glial cells in AD. Melatonin is a secretory product of the pineal gland; melatonin is a potent antioxidant and free radical scavenger and may play an important role in aging and AD. Melatonin decreases during aging and patients with AD have a more profound reduction of this indoleamine. Additionally, the antioxidant properties, the anti-amyloidogenic properties and anti-apoptotic properties of melatonin in AD models have been studied. In this article, we review the antiamyloidogenic and anti-apoptotic role of melatonin in AD.
Export Options
About this article
Cite this article as:
He Hongwen, Dong Weiguo and Huang Fang, Anti-Amyloidogenic and Anti-Apoptotic Role of Melatonin in Alzheimer Disease, Current Neuropharmacology 2010; 8 (3) . https://dx.doi.org/10.2174/157015910792246137
DOI https://dx.doi.org/10.2174/157015910792246137 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Literature Evidence and ARRIVE Assessment on Neuroprotective Effects of Flavonols in Neurodegenerative Diseases' Models
CNS & Neurological Disorders - Drug Targets EDITORIAL
Current Drug Therapy Editorial [Hot Topic: Regulation of Glutamate Synthesis Via Inhibition of Glutamate Carboxypeptidase II (GCPII): An Effective Method to Treat Central and Peripheral Nervous System Disorders (Guest Editors: Guido Cavaletti and Barbara Slusher)]
Current Medicinal Chemistry Immunophilin Dysfunction and Neuropathology
Current Medicinal Chemistry Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease
Current Drug Targets Patent Selections
Recent Patents on Drug Delivery & Formulation Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design The Role of Oxidative Stress in Huntington’s Disease: Are Antioxidants Good Therapeutic Candidates?
Current Drug Targets Editorial (Thematic Issue: Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Diseases: Molecular Targets)
Current Pharmaceutical Design Origin and Expansion of Trinucleotide Repeats and Neurological Disorders
Current Genomics Advances in Antioxidative Therapy of Multiple Sclerosis
Current Medicinal Chemistry Implications of VIP and PACAP in Parkinson’s Disease: What do we Know So Far?
Current Medicinal Chemistry Nitrones: A Potential New Alternative as Therapeutic Agents
Current Organic Chemistry Depressed or Demented: Common CNS Drug Targets? !
Current Drug Targets - CNS & Neurological Disorders Rhein-Huprine Derivatives Reduce Cognitive Impairment, Synaptic Failure and Amyloid Pathology in AβPPswe/PS-1 Mice of Different Ages
Current Alzheimer Research Neurological Disorders in Medical Use of <i>Cannabis</i>: An Update
CNS & Neurological Disorders - Drug Targets Clinical Characteristics and Possible Drug Targets in Autosomal Dominant Spinocerebellar Ataxias
CNS & Neurological Disorders - Drug Targets Organophosphate Induced Delayed Polyneuropathy
Medicinal Chemistry Reviews - Online (Discontinued) Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry